Abstract:Rong Liu, 1, &ast Min Zhu, 2, &ast Jiaojiao Chen, 3 Junwei Gai, 2 Jing Huang, 2 Yingqun Zhou, 1 Yakun Wan, 2 Chuantao Tu 4 1 Department of Gastroenterology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, People's Republic of China; 2 Shanghai Novamab Biopharmaceuticals Co., Ltd, Shanghai, 201318, People's Republic of China; 3 Department of Gastroenterology, Shanghai Fourth People's Hospital, Tongji University School of Medicine, Shanghai, 200434, People's Republic of China; 4 Department of Gastroenterology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, People's Republic of China &astThese authors contributed equally to this work Correspondence: Chuantao Tu; Yakun Wan, Email ; Background: No agents are currently available for the treatment or reversal of liver fibrosis. Novel antifibrotic therapies for chronic liver diseases are thus urgently needed. Connective tissue growth factor (CTGF) has been shown to contributes profoundly to liver fibrogenesis, which makes CTGF as a promising target for developing antifibrotic agents. Methods: In this study, we identified a novel nanobody (Nb) against human CTGF (anti-CTGF Nb) by phage display using an immunized camel, which showed high affinity and specificity in vitro. LX-2 cells, the immortalized human hepatic stellate cells, were induced by transforming growth factor beta1 (TGFβ 1) as an in vitro model of liver fibrosis to verify the antifibrotic activity of the anti-CTGF Nb. Results: Our data demonstrated that anti-CTGF Nb effectively alleviated TGFβ 1-induced LX-2 cell proliferation, activation, and migration, and promoted the apoptosis of activated LX-2 cells in response to TGFβ 1. Moreover, the anti-CTGF Nb remarkably reduced the levels of TGFβ 1, Smad2, and Smad3 expression in LX-2 stellate cells stimulated by TGFβ 1. Conclusion: Taken together, we successfully identified a novel Nb against human CTGF, which exhibited antifibrotic effects in vitro by regulating the biological functions of human stellate cells LX-2. Graphical Keywords: nanobody, connective tissue growth factor, liver fibrosis, hepatic stellate cells Graphical Chronic liver injury of various etiologies can lead to liver fibrosis characterized by excessive accumulation of extracellular matrix (ECM) in the liver. 1–3 If remain unresolved, liver fibrosis may progress to cirrhosis, liver failure, and even hepatocellular carcinoma (HCC). 1 Chronic fibrotic liver disease and cirrhosis represent a major global health challenge. However, there are currently no approved therapeutic agents to treat or reverse liver fibrosis. 1,2 Therefore, a deep understanding of molecular mechanisms underlying hepatic fibrogenesis is needed to identify potential targets for antifibrotic therapies. Hepatic stellate cells (HSCs) have been identified as the primary precursor cells of myofibroblasts (MFBs), which orchestrate the deposition of ECM in normal and fibrotic liver. 1–3 Upon liver injury, hepatocytes and nonparenchymal cells, such as Kupffer cells, endothelial cells, and neutrophil granulocytes, release cytokines and chemokines, ultimately activate HSCs to release their vitamin A and retinoid stores, and undergo dramatic phenotypic alterations, and transdifferentiate into MFBs. 1,3–5 Furthermore, the activated MFBs exhibit a variety of cellular processes such as proliferation, migration, contractility, and apoptosis resistance, accompanied by secretion of cytokines, chemokines, and ECM components. 4 Thus, targeting the activation of MFBs are emerging as a high potential a strategy for treating liver fibrosis. 1,6 Transforming growth factor beta (TGFβ) signaling is considered as a master profibrogenic pathway responsible for ECM production and plays a key role in the pathogenesis of liver fibrosis. 7–9 TGFβ1 is the principal isoform of TGFβ which mediates SMAD2/3 dependent pathway, commonly activating HSCs and stimulating the production of ECM synthesis. 7,8 Therefore, blocking TGFβ signaling represents an attractive antifibrotic therapy. 5,7 However, TGFβ is a multifunctional cytokine and has important roles in liver physiology, and its inhibition results in undesirable side effects, 5,7,10 which is a major challenge for translation into use of the clinic. Therefore, an improved understanding of the downstream regulatory mechanisms of TGF-β may help develop therapeutic strategies against liver fibrosis. 7 Connective tissue growth factor (CT -Abstract Truncated-

A Deactivation Factor of Fibrogenic Hepatic Stellate Cells Induces Regression of Liver Fibrosis in Mice

Liver Fibrosis Therapy Based on Biomimetic Nanoparticles Which Deplete Activated Hepatic Stellate Cells.

Ablation of serum response factor in hepatic stellate cells attenuates liver fibrosis

Targeting Transforming Growth Factor Βrii Expression Inhibits the Activation of Hepatic Stellate Cells and Reduces Collagen Synthesis

C1q/tumor Necrosis Factor-Related Protein-3 Acts As a Target Treating Hepatic Fibrosis

Perivenous Stellate Cells Are the Main Source of Myofibroblasts and Cancer‐Associated Fibroblasts Formed After Chronic Liver Injuries

KIF18A inactivates hepatic stellate cells and alleviates liver fibrosis through the TTC3/Akt/mTOR pathway

Hepatic stellate cells as key target in liver fibrosis

Single‐Cell Transcriptomic Analysis Reveals a Hepatic Stellate Cell–Activation Roadmap and Myofibroblast Origin During Liver Fibrosis in Mice

The combined induction of liver progenitor cells and the suppression of stellate cells by small molecules reverts chronic hepatic dysfunction

Autocrine CTHRC1 activates hepatic stellate cells and promotes liver fibrosis by activating TGF-β signaling

Sirt6 Alleviated Liver Fibrosis by Deacetylating Conserved Lysine 54 on Smad2 in Hepatic Stellate Cells

DNMT3a-mediated methylation of TCF21/hnRNPA1 aggravates hepatic fibrosis by regulating the NF-κB signaling pathway

Hepatocyte FoxO1 Deficiency Protects From Liver Fibrosis via Reducing Inflammation and TGF-β1-mediated HSC Activation

Lactoferrin as a therapeutic agent for attenuating hepatic stellate cell activation in thioacetamide-induced liver fibrosis

Inhibition of connective tissue growth factor suppresses hepatic stellate cell activation in vitro and prevents liver fibrosis in vivo

ATF3‐mediated transactivation of CXCL14 in HSCs during liver fibrosis

Molecular mechanism of hepatic stellate cell activation and antifibrotic therapeutic strategies

Identification and Characterization of a Novel Nanobody Against Human CTGF to Reveal Its Antifibrotic Effect in an in vitro Model of Liver Fibrosis

SNS-032 attenuates liver fibrosis by anti-active hepatic stellate cells via inhibition of cyclin dependent kinase 9

MFAP2 promotes HSCs activation through FBN1/TGF‐β/Smad3 pathway